Captopril

62571-86-2

C9H15NO3S

DMSO : >= 50 mg/mL (230.11 mM); H2O : >= 50 mg/mL (230.11 mM)

Metabolic Enzyme/Protease

Captopril (SQ-14534) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE). IC50 & Target: ACE^[1]. In Vitro: Captopril (SQ-14534) has been shown to have similar morbidity and mortality benefits to those of diuretics and beta-blockers in hypertensive patients. Captopril (SQ-14534) has been shown to delay the progression of diabetic nephropathy, and enalapril and lisinopril prevent the development of nephropathy in normoalbuminuric patients with diabetes^[1]. An equimolar ratio of the cis and trans states of Captopril (SQ-14534) exists in solution and that the enzyme selects only the trans state of the inhibitor that presents architectural and stereoelectronic complementarity with its substrate binding groove^[2].